Why This $73M Bet on Oral Eye Therapy Could Change Everything

Jan de Vries · 2026-10-02

Breye Therapeutics, a Danish biopharmaceutical company, just pulled off something impressive: an oversubscribed $73 million Series A round. That's a lot of confidence for a company developing oral treatments for retinal diseases. The round was co-led by Mission BioCapital and Novo Holdings, with existing investor Sound Bioventures and a handful of new backers including the Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures, and Pappas Capital. As part of the deal, Robert Blazej from Mission BioCapital and Lukas Ljungström will join the board. So what's the big deal? Let's break it down. ### The Problem With Current Treatments If you or someone you love has diabetic retinopathy, you know the drill: injections directly into the eye. Not exactly a walk in the park. These intravitreal treatments can help preserve vision in late-stage disease, but they're invasive, poorly tolerated, and adherence drops off fast. And for patients in the early or moderate stages of non-proliferative diabetic retinopathy (NPDR)? Options are painfully limited. That's where Breye comes in. ### A Pill Instead of a Needle Breye's lead candidate, danegaptide, is a first-in-class oral small molecule. Instead of injecting something into your eye, you swallow a pill. The drug works by stabilizing retinal vasculature, protecting against capillary breakdown and vascular leakage caused by chronic high blood sugar. Last year, Breye completed a Phase 1b trial in NPDR patients. The results? Danegaptide was well tolerated across all dose levels and showed early signs of clinical activity, including retinal imaging data consistent with reduced vascular leakage. That's a big deal because vascular leakage is one of the core pathologies of NPDR. The company also published a paper in Science Translational Medicine analyzing the preclinical and early clinical evidence for danegaptide. Not too shabby. ### The Market Opportunity Diabetic retinopathy affects about 130 million people worldwide. The current market for therapeutics is approaching $10 billion, and it could nearly double over the next decade with a predicted CAGR of 6.5%. That's a massive opportunity for a patient-friendly oral option. As Ulrik Mouritzen, CEO of Breye, put it: "This $73 million Series A financing... enables us to advance danegaptide, our pioneering, first-in-class oral treatment for diabetic retinopathy, to the next stage of clinical development – bringing a much-needed patient-friendly treatment option closer to those living with this debilitating eye disease." ### What's Next? Breye was founded in 2019 and emerged from stealth in 2022 with a $4.3 million seed round. Now, with this fresh capital, they're pushing danegaptide into the next phase of clinical development. They're also working on oral therapies for intermediate age-related macular degeneration and glaucoma. Robert Blazej from Mission BioCapital said, "Breye is emerging as a leader in the development of innovative retinal disease therapies... we believe Breye is uniquely positioned to address this unmet need." If Breye succeeds, it could mean no more eye injections for millions of patients. That's a future worth watching.